Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Dabur Pharma announces results for Fiscal 2006-07

May 17th, 2007

Dabur Pharma announces results for Fiscal 2006-07

Abstract:
Commenting on the growth, Dr. Anand Burman, Chairman Dabur Pharma Limited, said "FY 2006-07 was a milestone year for the company, a year of significant growth, research and innovation that led to the launch of an array of new products, including Nanoxel - the first indigenously developed nanotechnology based chemotherapy agent in the country".

Source:
moneycontrol.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025

New imaging approach transforms study of bacterial biofilms August 8th, 2025

Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025

Announcements

Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025

Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025

Japan launches fully domestically produced quantum computer: Expo visitors to experience quantum computing firsthand August 8th, 2025

ICFO researchers overcome long-standing bottleneck in single photon detection with twisted 2D materials August 8th, 2025

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project